UNSPSC 51411711: Papaverine nitrite

This classification denotes a vasodilating agent and phosphodiesterase inhibitor C20H21NO4.HNO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U8CZ4BHO2Z, chemically known as isoquinoline, 1-((3,4-dimethoxyphenyl)methyl)-6,7-dimethoxy-, compd. with nitrous acid (1:1), but more generally known as papaverine nitrite, which bears US NIH Compound Identifier 71586756. Most nations, for tariff and trade purposes, schedule papaverine nitrite under HS 29391900 and SITC 54141.

As of Q4 2014, PAPAVERINE NITRITE remains US FDA's Preferred Term for this commodity. SMILES: COC1CCC(CC1OC)CC2C3CC(C(CC3CCN2)OC)OC.N(=O)O.

UNSPSC 51411711 Papaverine nitrite is a Commodity code that reflects state and local procurement of prescription and non-prescription medications used in emergency medical care, public health programs, and institutional healthcare delivery. The code encompasses individual pharmaceutical products supplied in bulk or unit quantities to fire departments, health agencies, and cooperative purchasing consortia serving multiple jurisdictions. State and local buying bodies soliciting under this code include municipal fire departments, state health and human services agencies, and multistate cooperative purchasing alliances. Recent opportunities show demand for advanced life support medications (epinephrine, adenosine, diltiazem, and related agents), generic multi-source pharmaceuticals distributed through authorized wholesalers, and manufacturer-direct supply arrangements to support state pharmacy benefit programs.

Activity appears concentrated in the South and Upper Midwest. The City of Tampa's Purchasing Department issued an IFB for Advanced Life Support Medications (Bid No. 26-P-00188, due April 8, 2026) with an estimated contract value of $40,000 to supply Tampa Fire Rescue, including a 5 percent bid discount for Small Local Business Enterprise participation. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP for Generic Multi Source Pharmaceuticals and OTC Products (due March 26, 2026) serving multiple state and local facilities including Oregon, with vendor delivery through three authorized wholesalers and contract terms of two years. The Texas Health and Human Services Commission issued an RFI (HHS0017013, due April 3, 2026) to explore direct-to-manufacturer prescription fulfillment models outside traditional pharmacy benefit manager and group purchasing organization channels. All recent solicitations emphasize FDA compliance, cGMP certification, Drug Supply Chain Security Act compliance, expiration-date management, and OSHA hazard communication documentation.